Stock Scorer

DNA X, Inc. (SONM) · Insider trading

What DNA X's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.

Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$0
0 insiders
Net, 12 months
$0
bought less sold
Latest filing
2026-02-10
filings read to 2026-10-19

Bought and sold at the market, by month

Two years. Purchases above the line, sales below, in dollars.

2024-11: $8,394 sold 2025-01 2025-04: $176,926 sold 2025-06: $1.26M sold 2025-07 2026-01 2026-07
Bought Sold Largest month: $1.26M

Who traded, two years

InsiderBoughtSold TradesLast tradeHolds after
Lytton Laurence W10% owner – $1.26M 2 2025-06-30 0
Mulica Michael CDirector – $48,730 2 2025-04-23 73,292
Becher CharlesSee Remarks – $45,423 1 2025-04-23 62,668
Cassano James SDirector – $33,902 1 2025-04-23 49,126
Steenstra JackDirector – $33,902 1 2025-04-23 49,139
Crolius ClaytonChief Financial Officer – $16,869 1 2025-04-23 30,958
Wang JeffreyDirector – $6,493 1 2025-04-23 21,301

Open-market purchases and sales

Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.

DateInsiderTradeShares PriceValueHolds afterFiling
2025-06-30 Lytton Laurence W10% owner Sale 400,514 1.39 $556,714 0 Form 4
2025-06-26 Lytton Laurence W10% owner Sale 466,402 1.50 $699,603 400,514 Form 4
2025-04-23 Becher CharlesSee Remarks Sale 31,326 1.45 $45,423 62,668 Form 4
2025-04-23 Cassano James SDirector Sale 23,381 1.45 $33,902 49,126 Form 4
2025-04-23 Crolius ClaytonChief Financial Officer Sale 11,634 1.45 $16,869 30,958 Form 4
2025-04-23 Mulica Michael CDirector Sale 27,818 1.45 $40,336 73,292 Form 4
2025-04-23 Steenstra JackDirector Sale 23,381 1.45 $33,902 49,139 Form 4
2025-04-23 Wang JeffreyDirector Sale 4,478 1.45 $6,493 21,301 Form 4
2024-11-13 Mulica Michael CDirector Sale 2,559 3.28 $8,394 54,382 Form 4

Grants, exercises and other transactions

Pay, tax and paperwork rather than a choice to trade at the market price. Two years.

9 × grant or award
Show them
DateInsiderWhatShares PriceHolds afterFiling
2026-02-09 Mulica Michael CDirector, Acting CEO Grant or award A +50,000 – 54,071 Form 4
2026-02-09 Crolius ClaytonChief Financial Officer Grant or award A +35,000 – 36,719 Form 4
2025-03-31 Cassano James SDirector Grant or award A +46,728 – 72,507 Form 4
2025-03-31 Steenstra JackDirector Grant or award A +46,728 – 72,520 Form 4
2025-03-31 Mulica Michael CDirector Grant or award A +46,728 – 101,110 Form 4
2025-02-06 Becher CharlesSee Remarks Grant or award A +70,671 – 93,994 Form 4
2025-02-06 Crolius ClaytonChief Financial Officer Grant or award A +33,922 – 42,592 Form 4
2025-02-06 Liu Hao PeterDirector, Chief Executive Officer Grant or award A +63,604 – 269,388 Form 4
2024-11-12 Mulica Michael CDirector Grant or award A +14,124 – 56,941 Form 4

How to read it

Buy, sale
Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
Plan
A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
Holds after
The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
Value
Shares times the price the form reports, which is often an average over several fills on the day.

Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.

DNA X's scores and multiples ›